Corcept Therapeutics (CORT) Change in Accured Expenses (2010 - 2026)

Corcept Therapeutics has reported Change in Accured Expenses for 17 years, with the latest figure at $34.3 million in Q2 2026.

• Quarterly Change in Accured Expenses rose 380.67% year-over-year to $34.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $27.6 million (down 12.67% YoY) and the FY2025 annual result came in at $3.9 million, down 89.73% from the prior year.
• Change in Accured Expenses rose to $34.3 million in Q2 2026 per CORT's latest filing, from -$9.4 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $34.3 million in Q2 2026 and troughed at -$19.0 million in Q4 2023.
• A 5-year average of $4.9 million and a median of $6.1 million in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses sank 1714.07% in 2023, then surged 691.47% in 2025.
• Over 5 years, Change in Accured Expenses stood at $1.2 million in 2022, then tumbled by 1714.07% to -$19.0 million in 2023, then jumped by 156.24% to $10.7 million in 2024, then sank by 223.57% to -$13.2 million in 2025, then jumped by 359.26% to $34.3 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $34.3 million, -$9.4 million, and -$13.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.